论文部分内容阅读
目的探讨CYP2C19基因多态性与氯吡咯雷对血小板抑制率之间的关系。方法选取某院诊断为急性冠脉综合征患者76例,均口服氯吡格雷,利用血栓弹力图方法测定氯吡咯雷对血小板的抑制率,利用基因芯片试剂盒原理测定CYP2C19基因型。本试验共检测六种基因亚型。结果我国人群以CYP2C19*1*1,CYP2C19*1*2基因亚型为主。比较六种CYP2C19基因亚型患者氯吡咯雷对血小板的抑制率。结果无统计学差异,P>0.05。结论 CYP2C19基因型与氯吡咯雷对血小板抑制率无明显关系,所以,对于ACS患者无论CYP2C19基因型如何均应按指南推荐剂量使用氯吡咯雷。
Objective To investigate the relationship between CYP2C19 gene polymorphism and clopidogrel on platelet inhibition rate. Methods A total of 76 patients diagnosed as acute coronary syndrome in our hospital were treated with clopidogrel orally. The inhibition rate of clopidogrel to platelet was determined by thrombelastography. The CYP2C19 genotype was determined by gene chip kit principle. This test detects a total of six gene subtypes. Results Our population mainly CYP2C19 * 1 * 1, CYP2C19 * 1 * 2 gene subtype. The inhibitory rates of clopidogrel against platelets in six CYP2C19 subtypes were compared. The results showed no significant difference, P> 0.05. Conclusion There is no significant relationship between CYP2C19 genotype and clopidogrel on platelet inhibition rate. Therefore, for patients with ACS, chloropyroxir should be used at the recommended dose regardless of the CYP2C19 genotype.